ABSTRACT Schizophrenia is a debilitating neurodegenerative disorder which affects 1% of the global population and is caused by a complex interaction between the genotype and the environment making it difficult to identify the multitude of genes and the external causatives which may predispose an individual towards developing schizophrenia. Current pharmacotherapies available for the treatment of schizophrenia include typical and atypical antipsychotics but their clinical efficacy is compromised by the slow onset of effect and significant side-effect profile. Cannabidiol is a derivative of the Cannabis sativa plant which has shown antipsychotic potential in several preclinical and clinical studies. This review will highlight the results of these studies and discuss the need for further investigations into the neuropharmacology of Cannabidiol as an antipsychotic.
Buy this Article
|